Full cellular reprogramming using the Yamanaka factors (OCT4, SOX2, KLF4, c-MYC; OSKM) converts differentiated cells to induced pluripotent stem cells (iPSCs), carrying unacceptable risks of tumor formation (through MYC activation) and complete loss of cellular identity in the neuronal context. However, partial reprogramming—the controlled expression of Yamanaka factors at levels insufficient for full pluripotency but adequate to reset the epigenetic clock—selectively reverses senescence-associated epigenetic marks (H3K9me3, DNA methylation age) while preserving cell-type-specific transcription factor binding and chromatin architecture. This hypothesis proposes that a cyclinD1 (CCND1)-tethered version of the Yamanaka factors, expressed from a doxycycline-inducible AAV9 vector under a neuronal-specific promoter (Synapsin I), enables partial reprogramming that reverses neuronal senescence in AD and PD without oncogenic transformation or loss of neuronal identity. The CyclinD1 tag exploits the natural G1/S cell cycle checkpoint machinery to temporally limit Yamanaka factor activity to the S-phase window, preventing the sustained expression that drives full reprogramming.
...Curated pathway from expert analysis
flowchart TD
A["Neuronal Senescence<br/>p16INK4a p21CIP1 SA-beta-gal Accumulation"]
B["CCND1-Tethered OSKM Factors<br/>Doxycycline-Inducible AAV9 Synapsin-1"]
C["S-Phase Window Limited Expression<br/>G1/S Checkpoint Constrains Reprogramming"]
D["Epigenetic Clock Reset<br/>H3K9me3 and DNA Methylation Age Marks Reversed"]
E["Senescence Markers Cleared<br/>p16 p21 Reduced Greater than 70 percent"]
F["Neuronal Identity Preserved<br/>MAP2 NeuN Synapsin-I Greater than 95 percent"]
G["Mitochondrial Membrane Potential Restored<br/>Aggregate Clearance via Autophagy"]
H["Senescence Reversed Without Oncogenesis<br/>NANOG OCT4 SOX2 Below 5 percent iPSC"]
A --> B
B --> C
C --> D
D --> E
E --> F
E --> G
F --> H
G --> H
style B fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style H fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7No linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for OCT4 yet. Search RCSB →
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for OCT4,POU5F1,SOX2,KLF4,MYC,CCND1,CDKN2A,CDKN1A,MAP2,NEUN,SYN1,DNMT1,EZH2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF aged 5xFAD and A53T mice receive AAV9-Syn1-CCND1-OSKM at the efficacy dose, THEN no intracranial or systemic tumorigenesis will be detectable by 9.4T MRI and histopathology, and >95% of MAP2+/NeuN+ | Zero tumors on MRI/histology, ≥95% MAP2+/NeuN+ cells with neuronal morphology, neuronal marker expression within 5% of baseline | — no observation — | pending | 0.78 |
| IF aged 5xFAD and A53T transgenic mice receive a single bilateral intraventricular injection of AAV9-Syn1-CCND1-OSKM (1×10^11 vg/mouse) with 4-week doxycyline chow (1 mg/kg), THEN cortical and hippoca | ≥60% reduction in SA-β-gal+ cells, ≥70% decrease in CDKN2A/CDKN1A protein, ≥40% improvement in NOL discrimination index | — no observation — | pending | 0.72 |